030 Transient cortical blindness after coronary angiography: 2 cases report  by Ndom, Marie Solange & Mouine, Najat
© Elsevier Masson SAS. All rights reserved.
 
10 Archives of Cardiovascular Diseases Supplements (2011) 3, 1-25
patients. We sought to evaluate aspirin and clopidogrel response in elderly
patients soon after PCI and on chronic maintenance treatment.
Methods and Results: We prospectively included 93 elderly patients (≥
75 years) who underwent PCI from January 2008 to April 2009. All patients
were treated with aspirin and clopidogrel. We used a standardized point of
care assay VerifyNow® aspirin and VerifyNow® clopidogrel P2Y12 to mea-
sure aspirin and clopidogrel responsiveness with cut-offs previously validated
in clinical trials. Measurements were performed in-hospital after PCI (T1) and
5-6 weeks later (T2) when the patients had been on maintenance therapy (75
mg aspirin plus 75 mg clopidogrel once a day) for at least 1 week. Aspirin
non/poor responders were found in 10 % of patients at T1 and in 14% at T2.
Clopidogrel non/poor response was noted in 32% of patients at T1 and in 68%
at T2. Changes in platelet reactivity to clopidogrel was significant from T1 to
T2 (p-value <0.001), but not significant for aspirin. Multivariate analysis
revealed low hematocrit (Ht) to be independently associated with clopidogrel
non responsiveness at T1 (OR 2.99; 95% CI 1.04-8.59; p-value=0.042 for Ht
<35%) and T2 (OR 2.74; 95% CI 1.08-6.93; p-value=0.033 for Ht <40%).
Conclusions: The rate of biological non/poor response to dual antiplatelet
therapy in elderly patients soon after PCI was close to that reported in younger
patients. In contrast, there was high residual platelet reactivity under chronic
treatment with 75 mg of clopidogrel (almost two-thirds).
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Transient cortical blindness is rarely encountered after coronary angiog-
raphy or angioplasty. This paper reports 2 cases of transient cortical blindness
that occurred immediately after coronary angiography in 2 cases who admitted
for ischemic heart disease. Ophthalmological examination was normal and
neurological examination demonstrated cortical blindness and the absence of
any focal neurological deficit.
A computed tomography scan of the brain did not reveal any abnormality.
Sight returned spontaneously within 2 days and their vision gradually
improved. A search of the current literature for reported cases of transient cor-
tical blindness suggested that this is a rarely encountered complication of cor-
onary angiography and appears to probably carry no increased risk. 
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Purpose: Usefullness of Niacin in subjects with stable coronary heart dis-
ease [CHD], low HDL and endothelial dysfunction [ED] remains controver-
sial. Furthermore, benefits of its prescription after an acute coronary syndrome
[ACS] in pts with low HDL and ED is unknown.
Methods: The EVAN-ACS study was a double-blind randomised placebo-
controlled trial aiming at the evaluation of effects of Niacin on endothelial
function in subjects with low HDL (<0.4 g/l) and ED who recently suffered
from an ACS. Pts were screened over a 18 months period. Flow Mediated
Dilation [FMD] of the brachial artery was measured in the 7 days following
the ACS, and subjects with FMD<7% were randomized either to the Treat-
ment Group [TG] (Niacin 1000 mg/d) or to the Placebo Group [PG]. After
12 weeks, new measurement of FMD was performed.
Results: 75 pts with ED were randomised. Median age was 51 (45-61) and
92.6% of the pts were men. No significant baseline difference existed between
the two groups for age, gender, smoking, blood pressure, plasma lipoprotein
levels, CRP or FMD. After 12 weeks, FMD had significantly increased both
in the TG (median absolute change: +3.6%, p<0.001) and in the PG (+2.1%,
p<0.001), but the difference between the two groups was not significant
(p=0.87). In the same way, CRP, LDL-C and triglycerides significantly
decreased and HDL significantly increased in both groups, but these changes
were not statistically different from the TG to the PG (median absolute change
of CRP : -4.2 and –2.7 mg/l respectively in the TG and in the PG, p=0.63 /
LDL-C: -0.3 and -0.4 g/l mmol/l or mg/dl, p=0.84 / triglycerides: -0.51 and –
0.52 g/l, p=0.63 / HDL-C: +0.07 and +0.02 g/l, p=0.09).
Conclusions: In this trial, conducted in subjects with ED shortly after an
ACS, FMD increased both in the Niacin treated group and the placebo group,
but the extent of this rise was not significantly different. Larger studies and/or
higher niacin doses are required to better address this important topic.
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Purpose : Percutaneous treatment of unprotected left main coronary artery
(ULMCA) disease is progressively gaining acceptance in light of the first
results from drug-eluting stent registries or randomized trial. We thus assessed
early and mid-term results of patients treated for ULMCA disease in the
FRIEND registry.
Methods: After ethical committee approval and informed consent, all con-
secutive patients with unprotected left main stenoses treated with Taxus stents
were included in a multicenter prospective study from 23 centers. Major
adverse cardiac and cerebro-vascular events (MACCE) were adjudicated at
1,6,12,18 and 36 months by an independent committee. Immediate and 9-
month angiographic results were assessed by a central core lab (Corysis, St-
Denis, France). 
Results: From December 2005 to July 2006, 151 patients (pts) were
included, mean age 68 ± 11 years, 83 % male, 41 % unstable angina, 3 % dia-
betics, 24 % 3-vessel disease.The mean Euroscore was 4.1 ± 2.8. The LM ref-Abnormal aspect of the occipital lobes 
